Campbell & CO Investment Adviser LLC Makes New $254,000 Investment in Kenvue Inc. $KVUE

Campbell & CO Investment Adviser LLC bought a new position in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,159 shares of the company’s stock, valued at approximately $254,000.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Kenvue by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after buying an additional 10,600,682 shares in the last quarter. Third Point LLC purchased a new position in shares of Kenvue in the first quarter valued at $213,422,000. Maverick Capital Ltd. bought a new stake in shares of Kenvue during the 1st quarter valued at $203,036,000. Nuveen LLC purchased a new stake in Kenvue during the 1st quarter worth about $187,123,000. Finally, Voya Investment Management LLC lifted its holdings in Kenvue by 131.3% during the 1st quarter. Voya Investment Management LLC now owns 12,131,468 shares of the company’s stock worth $290,557,000 after purchasing an additional 6,886,784 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KVUE has been the topic of several analyst reports. Zacks Research upgraded Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on shares of Kenvue in a research note on Friday, October 24th. Citigroup lowered their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. UBS Group cut their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Finally, Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.23.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $16.27 on Tuesday. The company’s fifty day moving average price is $16.37 and its 200-day moving average price is $19.98. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The firm has a market capitalization of $31.17 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 2.43 and a beta of 0.71. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. The ex-dividend date is Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 110.67%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.